373 related articles for article (PubMed ID: 37502215)
1. Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries.
Smith DJ; Bi H; Hamman J; Ma X; Mitchell C; Nyirenda K; Monera-Penduka T; Oketch-Rabah H; Paine MF; Pettit S; Pheiffer W; Van Breemen RB; Embry M
Front Pharmacol; 2023; 14():1210579. PubMed ID: 37502215
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.
Anwar K; Nguyen L; Nagasaka M; Ou SI; Chan A
JTO Clin Res Rep; 2023 Feb; 4(2):100452. PubMed ID: 36568522
[TBL] [Abstract][Full Text] [Related]
4. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
Lemaitre F; Grégoire M; Monchaud C; Bouchet S; Saint-Salvi B; Polard E; ; ; ; ; ;
Therapie; 2022; 77(5):509-521. PubMed ID: 35618549
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics.
Sagawa K; Lin J; Jaini R; Di L
Pharm Res; 2023 Aug; 40(8):1927-1938. PubMed ID: 37231296
[TBL] [Abstract][Full Text] [Related]
6. Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir.
Gerhart J; Draica F; Benigno M; Atkinson J; Reimbaeva M; Francis D; Baillon-Plot N; Sidhu GS; Damle BD
AAPS J; 2023 Jul; 25(5):73. PubMed ID: 37468770
[TBL] [Abstract][Full Text] [Related]
7. Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.
Ye L; Fan S; Zhao P; Wu C; Liu M; Hu S; Wang P; Wang H; Bi H
Acta Pharm Sin B; 2023 Jun; 13(9):3598-637. PubMed ID: 37360014
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy.
Zhang F; Liu W; Huang J; Chen QL; Wang DD; Zou LW; Zhao YF; Zhang WD; Xu JG; Chen HZ; Ge GB
Acta Pharmacol Sin; 2022 Apr; 43(4):1072-1081. PubMed ID: 34183756
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
[TBL] [Abstract][Full Text] [Related]
11. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
12. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968
[TBL] [Abstract][Full Text] [Related]
13. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
[TBL] [Abstract][Full Text] [Related]
14. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.
Loos NHC; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2023 Jun; 162():114636. PubMed ID: 37004323
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
Sindelar M; McCabe D; Carroll E
J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
[TBL] [Abstract][Full Text] [Related]
17. The Chinese herb Styrax triggers pharmacokinetic herb-drug interactions
Zhang F; Zhang T; Gong J; Fang Q; Qi S; Li M; Han Y; Liu W; Ge G
Front Pharmacol; 2022; 13():974578. PubMed ID: 36110541
[TBL] [Abstract][Full Text] [Related]
18. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
[TBL] [Abstract][Full Text] [Related]
19. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
[TBL] [Abstract][Full Text] [Related]
20. PBPK Modeling of PAXLOVID
Jaini R; Lin J; Di L; Sagawa K
J Pharm Sci; 2024 Jan; 113(1):64-71. PubMed ID: 37805075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
